Kiniksa Q4 ARCALYST rev $71.2M (+15% YoY); FY2024 guidance $360-380M

Kiniksa Pharmaceuticals International, plc

2023-FY EPS reported $0.20 revenue$270,259,000

ARCALYST net product revenue $71.2M Q4 2023, $233.2M full-year 2023; ~9% of target 14,000 patients active on therapy.
2024 ARCALYST revenue guidance $360-380M, ~59% YoY growth at midpoint.
Q4 net income $25.2M vs $4.5M YoY; cash $206.4M, no debt, funds operations into at least 2027.
Abiprubart Phase 2 Cohort 4 data and new development indication expected April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Kiniksa Pharmaceuticals International, plc reported fourth quarter and full-year 2023 results: revenue $71.2 million and $233.2 million.

Period: fourth quarter and full-year 2023
Revenue: $71.2 million and $233.2 million
Result: reported results

Exact text from the filing

ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Kiniksa Pharmaceuticals International, plc reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 28, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-24-028472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.